0001387131-23-011227.txt : 20230918 0001387131-23-011227.hdr.sgml : 20230918 20230918082834 ACCESSION NUMBER: 0001387131-23-011227 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230918 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230918 DATE AS OF CHANGE: 20230918 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 231260173 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K 1 tnxp-8k_091823.htm CURRENT REPORT
0001430306 false 0001430306 2023-09-18 2023-09-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): September 18, 2023

 

TONIX PHARMACEUTICALS HOLDING CORP.  

(Exact name of registrant as specified in its charter)

 

Nevada 001-36019 26-1434750

(State or Other Jurisdiction  

of Incorporation)  

(Commission  

File Number) 

(IRS Employer  

Identification No.)  

 

26 Main Street, Chatham, New Jersey 07928  

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 904-8182

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TNXP The NASDAQ Capital Market

   

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On September 18, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced data relevant to the proposed mechanism of the Company’s TNX-1900 (intranasal potentiated oxytocin) product candidate in treating chronic migraine in a poster and an oral presentation at the 2023 International Headache Congress (“IHC”), held September 14, 2023 to September 17, 2023, entitled Human trigeminal ganglia possess oxytocin receptors on CGRP positive neurons: expression increased by inflammation (the “Presentation”). A copy of the press release that discusses this matter is filed as Exhibit 99.01 hereto and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01.Other Events.

 

On September 18, 2023, the Company announced the Presentation at the IHC conference by David C. Yeomans, Ph.D. Data from the Presentation shows that oxytocin receptors are co-expressed with calcitonin gene-related peptide (“CGRP”) on isolated human trigeminal ganglia neurons, similar to previous findings in animal trigeminal ganglia. The inflammatory cytokine IL-6 upregulated expression of oxytocin receptors on human trigeminal neurons, consistent with the previously observed impact of inflammation on the potency of oxytocin. In animals, oxytocin has been shown to functionally inhibit the excitability of trigeminal neurons, which is consistent with oxytocin inhibiting the release of CGRP at trigeminal nerve terminals, which the Company believes relates to its mechanism in preventing migraines. The data also demonstrates that oxytocin receptors are present on human trigeminal ganglia neurons, and that these same neurons express CGRP, a key peptide in the pathogenesis of migraine. These data support the proposed mechanism of TNX-1900, which the Company believes inhibits the release of CGRP from trigeminal neurons that otherwise would trigger a cascade leading to migraine. In addition, the inflammatory mediator IL-6 induces robust upregulation of oxytocin receptors on human trigeminal ganglia neurons. In the presence of inflammation, which is persistently present in chronic migraine, there is a robust increase in the expression of both oxytocin receptors and CGRP in human trigeminal neurons.

Forward- Looking Statements

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits.

 

(d)  

Exhibit 

No. 

   Description.
   

99.01

104 

  

Press Release of the Company, dated September 18, 2023

Cover Page Interactive Data File (embedded within the Inline XBRL document) 

 

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: September 18, 2023 By: /s/ Bradley Saenger  
  Bradley Saenger
  Chief Financial Officer

 

 

 

 

 EX-99.01 2 ex99-01.htm PRESS RELEASE

 

Tonix Pharmaceuticals 8-K

Exhibit 99.01

 

Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress

 

 

Oxytocin receptors and CGRP are co-expressed on human trigeminal ganglia neurons and their expression is increased in inflammation

 

Human tissue data support the proposed mechanism of action of TNX-1900 in treating headache: oxytocin treatment blocks the release of CGRP

 

CHATHAM, N.J., September 18, 2023 – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that David C. Yeomans, Ph.D. presented data relevant to the proposed mechanism of TNX-1900 (intranasal potentiated oxytocin) in treating chronic migraine in a poster and an oral presentation at the 2023 International Headache Congress (IHC), being held September 14-17, 2023, in Seoul, South Korea. The poster and oral presentation titled, “Human trigeminal ganglia possess oxytocin receptors on CGRP positive neurons: expression increased by inflammation,” include research sponsored by and licensed to Tonix Pharmaceuticals. Professor Yeomans was a founder of Trigemina, which Tonix acquired, and he remains a consultant to Tonix. A copy of the poster is available under the Scientific Presentations tab of the Tonix Pharmaceuticals corporate website at www.tonixpharma.com.

The presentations show that oxytocin receptors are co-expressed with calcitonin gene-related peptide (CGRP) on human trigeminal ganglia neurons, which is similar to Professor Yeomans’ previous findings in animal trigeminal ganglia. The inflammatory cytokine IL-6 upregulated expression of oxytocin receptors on human trigeminal neurons, consistent with the previously observed impact of inflammation on the potency of oxytocin. In animals, oxytocin has been shown to functionally inhibit the excitability of trigeminal neurons, which is consistent with oxytocin inhibiting the release of CGRP at trigeminal nerve terminals.1

“In animal studies, oxytocin has been shown to inhibit trigeminal neurons which we believe relates to its mechanism in preventing migraines,”1 said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “The data presented at 2023 IHC by Professor Yeomans shows that oxytocin receptors are present on human trigeminal ganglia neurons, and that these same neurons express CGRP, a key peptide in the pathogenesis of migraine. These data support the proposed mechanism of TNX-1900, which we believe inhibits the release of CGRP from trigeminal neurons that otherwise would trigger a cascade leading to migraine.”

“Similar to animals, human trigeminal ganglia neurons express oxytocin receptors and also co-express CGRP,” said Professor Yeomans. “In addition, the inflammatory mediator IL-6 induces robust upregulation of oxytocin receptors on human trigeminal ganglia neurons. In the presence of inflammation, which is persistently present in chronic migraine, there is a robust increase in the expression of both oxytocin receptors and CGRP in human trigeminal neurons.”

In February 2023, Tonix initiated enrollment in the Phase 2 ‘PREVENTION’ study of TNX-1900 for the prevention of migraine headache in chronic migraineurs. Topline results from the study are expected in the fourth quarter of 2023. In addition, TNX-1900 is also being evaluated in investigator-initiated Phase 2 trials in adolescent obesity (initiated July 2023), binge eating disorder and social anxiety disorder.

1.Tzabazis A, et al. Cephalalgia. 2016. 36(10):943-50.

 

 

 

 

Tonix Pharmaceuticals Holding Corp.*

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead development CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia, having completed enrollment of a potentially confirmatory Phase 3 study in the third quarter of 2023, with topline data expected in the fourth quarter of 2023. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Topline results from a proof-of-concept Phase 2 study were reported in the third quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily oral formulation being developed as a treatment for major depressive disorder (MDD), that completed enrollment in a Phase 2 proof-of-concept study in the third quarter of 2023, with topline results expected in the fourth quarter of 2023. TNX-4300 (estianeptine) is a single isomer version of TNX-601, a small molecule oral therapeutic in preclinical development to treat MDD, Alzheimer’s disease and Parkinson’s disease. Relative to tianeptine, estianeptine lacks activity on the µ-opioid receptor while maintaining activity in the rat Novel Object Recognition test in vivo and the ability to activate PPAR-β/δ and neuroplasticity in tissue culture. TNX-1900 (intranasal potentiated oxytocin), is in development for preventing headaches in chronic migraine, and has completed enrollment in a Phase 2 proof-of-concept study with topline data expected in the fourth quarter of 2023. TNX-1900 is also being studied in binge eating disorder, pediatric obesity and social anxiety disorder by academic collaborators under investigator-initiated INDs. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the fourth quarter of 2023. Tonix’s rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 was initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases. The infectious disease development portfolio also includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals.

 

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

 

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. Intravail is a registered trademark of Aegis Therapeutics, LLC, a wholly owned subsidiary of Neurelis, Inc. All other marks are property of their respective owners.

 

This press release and further information about Tonix can be found at www.tonixpharma.com.

 

 

 

 

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2023, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris

Tonix Pharmaceuticals

investor.relations@tonixpharma.com

(862) 904-8182

 

Peter Vozzo

ICR Westwicke

peter.vozzo@westwicke.com

(443) 213-0505

 

Media Contact

Ben Shannon

ICR Westwicke

ben.shannon@westwicke.com

(919) 360-3039

 

 

 

 

 EX-101.SCH 3 tnxp-20230918.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tnxp-20230918_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tnxp-20230918_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Sep. 18, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 18, 2023
Entity File Number 001-36019
Entity Registrant Name TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key 0001430306
Entity Tax Identification Number 26-1434750
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 26 Main Street
Entity Address, City or Town Chatham
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07928
City Area Code (862)
Local Phone Number 904-8182
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TNXP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tnxp-8k_091823_htm.xml IDEA: XBRL DOCUMENT 0001430306 2023-09-18 2023-09-18 iso4217:USD shares iso4217:USD shares 0001430306 false 8-K 2023-09-18 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / M " 4L0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "00S)7 M)!Z;HJT #X 0 &@ @ &K$0 >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " "00S)799!YDAD! #/ P $P M @ &0$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" ( #:$P ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tonixpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tnxp-20230918.xsd tnxp-20230918_lab.xml tnxp-20230918_pre.xml tnxp-8k_091823.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tnxp-8k_091823.htm": { "nsprefix": "Tnxp", "nsuri": "http://tonixpharma.com/20230918", "dts": { "schema": { "local": [ "tnxp-20230918.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "tnxp-20230918_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20230918_pre.xml" ] }, "inline": { "local": [ "tnxp-8k_091823.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://tonixpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-09-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp-8k_091823.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp-8k_091823.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001387131-23-011227-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-23-011227-xbrl.zip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